6826 — Shanghai Haohai Biological Technology Co Share Price
Last trade - 00:00- HK$6.31bn
- HK$4.16bn
- CNY2.65bn
- 87
- 62
- 60
- 85
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.64 | ||
| PEG Ratio (f) | 0.56 | ||
| EPS Growth (f) | 23.37% | ||
| Dividend Yield (f) | 2.81% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.03 | ||
| Price to Tang. Book | 1.29 | ||
| Price to Free Cashflow | 15.88 | ||
| Price to Sales | 2.2 | ||
| EV to EBITDA | 6.02 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.94% | ||
| Return on Equity | 7.45% | ||
| Operating Margin | 19.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 1,604.33 | 1,332.43 | 1,766.99 | 2,130.28 | 2,654.04 | 3,151.38 | 3,684.47 | 11.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -10.6 | -43.77 | +53.61 | -37.33 | +93.93 | +26.46 | +17.78 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.
Directors
- Yongtai Hou CHM (54)
- Minjie Tang CFO (42)
- Jianying Wu GMG (51)
- Caixia Ren DGM (57)
- Wenbin Wang DGM (48)
- Jundong Zhang DGM (40)
- Ping Huang EDR (39)
- Yiyi Chen EDR (34)
- Min Tian SEC
- Ming Huang NED (44)
- Jie You NED (53)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 24th, 2007
- Public Since
- April 30th, 2015
- No. of Shareholders
- 6,720
- No. of Employees
- 2,158
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 168,707,203
- Address
- 4F, No 2 Building, Alley 139, SHANGHAI, 200336
- Web
- https://www.3healthcare.com/
- Phone
- +86 2152293555
- Contact
- Min Tian
- Auditors
- Ernst & Young LLP
Upcoming Events for 6826
Similar to 6826
Acotec Scientific Holdings
Stock Exchange of Hong Kong Limited
Beijing Airdoc Technology Co
Stock Exchange of Hong Kong Limited
AK Medical Holdings
Stock Exchange of Hong Kong Limited
AMCO United Holding
Stock Exchange of Hong Kong Limited
Angelalign Technology
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:10 UTC, shares in Shanghai Haohai Biological Technology Co are trading at HK$37.40. This share price information is delayed by 15 minutes.
Shares in Shanghai Haohai Biological Technology Co last closed at HK$37.40 and the price had moved by -9.44% over the past 365 days. In terms of relative price strength the Shanghai Haohai Biological Technology Co share price has underperformed the FTSE Developed Asia Pacific Index by -5.48% over the past year.
The overall consensus recommendation for Shanghai Haohai Biological Technology Co is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Shanghai Haohai Biological Technology Co dividend yield is 2.89% based on the trailing twelve month period.
Last year, Shanghai Haohai Biological Technology Co paid a total dividend of CNY1.00, and it currently has a trailing dividend yield of 2.89%. We do not have any data on when Shanghai Haohai Biological Technology Co is to next pay dividends.
We do not have data on when Shanghai Haohai Biological Technology Co is to next pay dividends. The historic dividend yield on Shanghai Haohai Biological Technology Co shares is currently 2.89%.
To buy shares in Shanghai Haohai Biological Technology Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$37.40, shares in Shanghai Haohai Biological Technology Co had a market capitalisation of HK$6.31bn.
Here are the trading details for Shanghai Haohai Biological Technology Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6826
Based on an overall assessment of its quality, value and momentum Shanghai Haohai Biological Technology Co is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Shanghai Haohai Biological Technology Co is HK$69.92. That is 86.96% above the last closing price of HK$37.40.
Analysts covering Shanghai Haohai Biological Technology Co currently have a consensus Earnings Per Share (EPS) forecast of CNY3.08 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shanghai Haohai Biological Technology Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -9.76%.
As of the last closing price of HK$37.40, shares in Shanghai Haohai Biological Technology Co were trading -4.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shanghai Haohai Biological Technology Co PE ratio based on its reported earnings over the past 12 months is 10.64. The shares last closed at HK$37.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Shanghai Haohai Biological Technology Co's management team is headed by:
- Yongtai Hou - CHM
- Minjie Tang - CFO
- Jianying Wu - GMG
- Caixia Ren - DGM
- Wenbin Wang - DGM
- Jundong Zhang - DGM
- Ping Huang - EDR
- Yiyi Chen - EDR
- Min Tian - SEC
- Ming Huang - NED
- Jie You - NED